What Moved ACADIA's Score
ACADIA Pharmaceuticals' (ACAD) Performance Score gained 3.0 points between August 4 and August 9, a real weekly move for a stock that had spent most of the year near the middle of the pack. The score peaked at 5.1 out of 10 before cooling to 4.6 as some of that momentum faded this week, and the move didn't happen quietly. Shares are still up 27.95% over the past three months and 11.29% over the past month, even after today's 3.63% pullback.
Price action tells most of the story. ACAD trades at $28.38, down 3.63% today and now 4.92% below its 52-week high of $29.85. RSI, a momentum gauge that flags a stock as overbought above 70, has cooled to 62.55 after touching that threshold last week.
The stock's beta of 0.80, a measure of how much it swings relative to the broader market, hasn't stopped it from putting up one of its stronger runs in years. That combination, a real fundamental catalyst plus a week of strong momentum, pushed the Performance Score up three full points before some of that momentum began fading this week.
The fundamental catalyst is NUPLAZID, ACADIA's approved treatment for hallucinations and delusions tied to Parkinson's disease psychosis. It generated $1.07 billion in revenue over the trailing year, up from $726 million three years ago. Net income of $391 million on that revenue gives ACADIA a P/E ratio of 11.51, cheap relative to most biotech peers still burning cash on unapproved pipelines.
NUPLAZID isn't carrying the company alone anymore either. ACADIA's own Q2 2026 results point to $1.24 to $1.30 billion in full-year revenue, with DAYBUE, its Rett syndrome treatment, now contributing alongside it.
ACADIA isn't a one-drug story anymore, either. Pimavanserin, the same compound behind NUPLAZID, is in Phase 3 trials for Alzheimer's disease psychosis and negative symptoms of schizophrenia, with results expected later this year. Two earlier-stage candidates, ACP-044 and ACP-319, are working through Phase 2 and Phase 1 respectively.
None of the Phase 3 or earlier-stage programs have reported yet, so the current score move is being driven by what's already approved and already profitable, NUPLAZID and DAYBUE, not speculation about what might read out next.
Zoom out and the run looks even more consistent. ACAD is up 61.43% over five years, a stretch that includes roughly two years of sideways trading while NUPLAZID's revenue base quietly built up in the background. Return on equity of 31.86% and return on assets of 23.40% both rank well above the typical biotech name, where plenty of companies still post negative returns on capital while burning cash on unapproved pipelines.
How Krystal Biotech and Alkermes Compare
ACADIA isn't the strongest performer in its own peer group. Krystal Biotech posts an 8.7 Performance Score, the highest of the three, backed by a 5-year return of 484.44% and a Health Score of 8.4. Krystal's approved gene therapy for a rare skin disease, alongside a Phase 3 pipeline of its own, has produced one of the stronger multi-year runs in the entire biotech sector.
Alkermes sits in the middle. Its Performance Score of 7.6 also beats ACADIA's, though its 3-month return of 27.09% is now essentially in line with ACADIA's own 27.95% gain over the same stretch. Its Health Score of 5.5 is still the weakest of the group, and its Risk Score of 7.0 is the highest, well above ACADIA's.
Put the three side by side and a pattern shows up. Krystal Biotech is the fundamentals-and-performance leader, Alkermes trades short-term momentum for a rougher risk profile, and ACADIA sits in between: a smaller Performance Score than either peer, but the calmest risk profile of the group by a wide margin. None of the three pay a dividend, and that's normal for biotech, where free cash flow gets reinvested into clinical trials instead of paid out to shareholders.
ACADIA's free cash flow per share of 1.25 is the highest of the three relative to its share price, another data point behind its comparatively low Risk Score.
The Risk Picture for a Mid-Cap Biotech
A Risk Score of 4.2, where a lower number means lower risk, stands out in a sector where volatility is usually the price of admission. Most biotech names in the Stoxcraft universe carry Risk Scores well above 5, reflecting binary trial outcomes, thin cash runways, and single-product dependency. ACADIA's score is meaningfully below that norm.
Part of that calm comes from ACADIA's balance sheet. Total debt of $52 million against $1.23 billion in equity gives it a current ratio of 3.83 and a cash flow to debt ratio of 2.10, both signs the company can fund its own pipeline without leaning on dilutive financing. An Altman Z-Score of 7.18, a bankruptcy-risk gauge where higher means safer, puts it well outside distress territory.
None of that guarantees the next leg of the story goes ACADIA's way. The expanded pimavanserin indications are still in Phase 3, and biotech Phase 3 readouts are where low-risk scores can change fast, in either direction. What today's Risk Score of 4.2 does capture is that the company isn't relying on those readouts to stay solvent.
NUPLAZID and DAYBUE's existing revenue funds the pipeline on their own, which is exactly the kind of setup that keeps a Risk Score low even while binary trial outcomes sit ahead on the calendar. For now, the combination of a still-elevated Performance Score, a low Risk Score, and profitable existing operations is a setup investors don't see often in this corner of healthcare.
For a broader view of how ACAD, KRYS, and ALKS stack up against the rest of the biotech industry, the Stoxcraft Screener lets you filter by Health, Performance, and Risk Score across the sector.
